Danaher (NYSE:DHR) Price Target Raised to $278.00

Danaher (NYSE:DHR) had its price objective upped by Evercore ISI from $275.00 to $278.00 in a research report released on Tuesday morning, Benzinga reports. Evercore ISI currently has an outperform rating on the conglomerate’s stock.

DHR has been the subject of several other research reports. The Goldman Sachs Group raised their price objective on shares of Danaher from $225.00 to $250.00 and gave the company a neutral rating in a research note on Wednesday, July 24th. Barclays lifted their price target on shares of Danaher from $270.00 to $285.00 and gave the stock an equal weight rating in a research note on Wednesday, July 24th. Bank of America lifted their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a neutral rating in a research note on Wednesday, July 24th. Wells Fargo & Company began coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an equal weight rating and a $280.00 price target for the company. Finally, TD Cowen lifted their price target on shares of Danaher from $290.00 to $310.00 and gave the stock a buy rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, Danaher has a consensus rating of Moderate Buy and a consensus price target of $282.12.

Danaher Trading Down 0.2 %

NYSE DHR opened at $270.03 on Tuesday. The firm has a 50 day simple moving average of $271.07 and a 200-day simple moving average of $258.56. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher has a one year low of $182.09 and a one year high of $281.70. The firm has a market cap of $200.01 billion, a price-to-earnings ratio of 45.77, a PEG ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the firm posted $2.05 earnings per share. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. Equities research analysts anticipate that Danaher will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s payout ratio is currently 18.31%.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,659 shares of company stock worth $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On Danaher

Several institutional investors and hedge funds have recently made changes to their positions in DHR. Vanguard Group Inc. boosted its position in shares of Danaher by 7.4% in the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after buying an additional 4,163,657 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Danaher by 12.0% in the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after purchasing an additional 2,998,161 shares in the last quarter. Swedbank AB purchased a new position in Danaher in the 1st quarter valued at about $676,545,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in Danaher by 214.4% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock valued at $711,051,000 after purchasing an additional 2,096,038 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Danaher by 10.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after purchasing an additional 1,619,586 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.